Drugs / GB104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05943041 | Apr → Dec 2023 | rectosigmoid junction cancer | GILongevity | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05943041 ↗ |
| Modality | Other / unclassified | “GB104 is a live biotherapeutic product consisting of a lyophilized formulation of a single strain of bacterium.” NCT05943041 ↗ |
| Route | Oral | “The dosing regimen for the study involves the oral administration of the experimental drug once a day.” NCT05943041 ↗ |